Effect of N, N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine against virus-induced encephalitis in mice).
N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (TSKI-VI) proved to be significantly effective against lethal vaccinia, pseudorabies and Mengo virus-induced encephalitis in different strains of mice when administered subcutaneously (s.c.) in doses of 20 mg/kg body weight, twice daily, for a period of five days. The strongest effects occurred in vaccinia virus-infected mice, and the degree of protection was both dose- and virus-dependent. Titres of vaccinia virus in brains of infected mice were slightly lower in TSKI-VI or methisazone-treated mice as compared to virus controls.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004660:Encephalitis / Q000188:drug therapy*; D004769:Enterovirus Infections / Q000188:drug therapy*; D005260:Female; D008297:Male; D008574:Mengovirus; D008720:Methisazone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D010879:Piperazines / Q000627:therapeutic use*; D011557:Pseudorabies / Q000188:drug therapy*; D013882:Thiosemicarbazones / Q000627:therapeutic use*; D014615:Vaccinia / Q000188:drug therapy*
D010879:Piperazines; D013882:Thiosemicarbazones; C023484:TSKI-VI; D008720:Methisazone